Analyser av Moberg Pharma

Moberg Pharma (Q2 Review): Brand approval clears the path for Europe as the Karo deal extends to APAC and China - Redeye

Moberg Pharma delivered a strong Q2 2026 report, with sales well ahead of Redeye's forecasts.

Moberg Pharma (Q2 Initial take): Growth accelerates further, launch timeline reconfirmed - Redeye

Redeye provides its initial take on Moberg Pharma's Q2 report, which saw sales exceed expectations and growth accelerate further, driven by ...

Redeye • Igår 08:39

Moberg Pharma: Fast-tracks China entry - Redeye

This morning, Moberg Pharma and Karo Healthcare announced an expansion of their licensing agreement for MOB-015 (Terclara®), now including t...

Redeye • 08 jun 08:53

Moberg Pharma (Q1 Review): APAC Expansion strengthens long-term growth case - Redeye

Moberg Pharma delivered a solid Q1 2026 report with sales exceeding expectations and a significantly stronger EBIT than forecast, driven by ...

Redeye • 13 maj 07:06

Moberg Pharma (Q1 Initial take): Momentum continues - Redeye

Redeye provides its initial take on Moberg Pharma’s Q1 report, which saw sales slightly exceed expectations and margins come in significantl...

Redeye • 12 maj 08:50

Moberg Pharma: APAC expansion further de-risks commercial path - Redeye

Moberg Pharma and Karo Healthcare have announced an expansion of their licensing agreement for MOB-015 (Terclara®), now including Australia,...

Redeye • 27 apr 07:03

Moberg Pharma (Q4 Review): Solid ending to a breakthrough year - Redeye

Redeye views the Q4 report as a sizable top-line beat, exceeding forecasts by 110% despite the quarter being a seasonal low.

Redeye • 19 feb 13:30

Moberg Pharma (Q4 Initial take): Sales ahead of forecast - Redeye

Redeye provides its initial take on Moberg Pharma’s Q4 report, where sales greatly exceeded our expectations.

Redeye • 17 feb 09:00

Moberg Pharma (Q3 Review): European footprint expanded, strengthening mid-/long-term outlook - Redeye

Redeye views the Q3 report as solid, with sales slightly ahead of expectations and tighter cost control than anticipated.

Redeye • 14 nov 2025 08:10

Moberg Pharma (Q3 initial take): Solid cost control and sales slightly ahead - Redeye

Redeye comments on Moberg Pharma’s Q3 report, in which sales came in slightly ahead of our forecast at SEK4.

Redeye • 11 nov 2025 08:58

Moberg Pharma: Transformative Europe-wide partnership with Karo Healthcare accelerates MOB-015/Terclara rollout - Redeye

Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement with Karo Healthcare for the commercialisat...

Redeye • 05 nov 2025 10:42

Moberg Pharma: Terclara is the market leader in both Sweden and Norway - Redeye

Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.

Redeye • 13 aug 2025 09:04

Moberg Pharma Q2: Teclara is the clear market leader in both Sweden and Norway - Redeye

Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.

Redeye • 12 aug 2025 08:51

Moberg Pharma: A very promising Norwegian launch - Redeye

Moberg Pharma successfully launched Teclara in Sweden last year, and the early initial feedback from Norway based on April and May is powerf...

Redeye • 16 jun 2025 09:29

Moberg Pharma Q1: In the midst of the high season - Redeye

Q1 confirms that Terclara defends a leading market position in Sweden and that the Norwegian launch is well underway into the high season, e...

Redeye • 14 maj 2025 11:16

Moberg Pharma Q1: A strong start ahead of the high season - Redeye

Q1 confirms that Moberg’s Terclara is the market leader in Sweden and that Terclara is on track for a Norwegian launch into the current high...

Redeye • 13 maj 2025 11:06

Moberg Pharma Q4’2024: All eyes on the European market - Redeye

Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated during the quarter.

Redeye • 12 feb 2025 07:25

Moberg Pharma Q4’2024: Primary focus on Europe - Redeye

Redeye comments on the Q4 report from Moberg Pharma.

Redeye • 11 feb 2025 10:41

Moberg Pharma: Expand Nordic Launch to Norway - Redeye

Redeye comments on the ongoing launch in Norway of Terclara.

Redeye • 03 feb 2025 11:28

Moberg Pharma: Additional Terbinafine supplier secured - Redeye

Redeye comments on a new additional supplier of Terbinafine that already holds an EU certificate of Suitability.

Redeye • 18 dec 2024 08:52

Moberg Pharma: Primary endpoint in Phase 3 study not met - Redeye

Redeye comments on the press release from Moberg Pharma last night.

Redeye • 11 dec 2024 07:23

Moberg Pharma Q3’2024: Launch in focus awaiting top line data - Redeye

Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Terclara in Sweden.

Redeye • 13 nov 2024 07:28

Moberg Pharma Q3’2024: Positive sales development awaiting US news - Redeye

Redeye comments on the Q3 report from Moberg Pharma.

Redeye • 12 nov 2024 08:44

Moberg Pharma: Valuation drops amid increased uncertainty - Redeye

Redeye comments on the news about the company’s lower-than-expected number of patients who have achieved clinical cure in the blinded subset...

Redeye • 16 sep 2024 09:27

Moberg Pharma: A setback for the US study - Redeye

Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.

Redeye • 13 sep 2024 08:58

Moberg Pharma: The Swedish market leader - Redeye

Redeye views the Q2 report as further confirmation of a successful strategy to already arrive at being the Swedish market leader.

Redeye • 14 aug 2024 08:09

Moberg Pharma: Powerful launch in Sweden - Redeye

Redeye saw a report where sales exceeded our expectations.

Redeye • 13 aug 2024 09:31

Moberg Pharma: Strong subscription rate for Warrants - Redeye

Redeye comments on the outcome of the T02 and the directed issue to the top guarantors, which brought in a strong SEK 336m before costs.

Redeye • 25 jun 2024 07:33

Moberg Pharma: Securing capital through commitments and top guarantee - Redeye

Redeye comments on the news that Moberg Pharma has secured the exercise of warrants and entered into a top guarantee.

Redeye • 11 jun 2024 09:09

Moberg Pharma: Subscription price set for Warrants - Redeye

Redeye comments on the subscription price and the strong start of the Terclara launch.

Redeye • 03 jun 2024 07:25

Moberg Pharma: Positive momentum - Redeye

Redeye views the Q1 report as a confirmation of the progress made with the first sales of Terclara in the books and processes proceeding as ...

Redeye • 08 maj 2024 11:04

Moberg Pharma Q1’2024: First sales of Terclara – results in line - Redeye

Redeye saw a report where the first sales were reported for Terclara, and the cost aligned with expectations.

Redeye • 07 maj 2024 09:27

Moberg Pharma: New Terbinafinee supplier has been submitted - Redeye

Redeye views the news from Moberg Pharma that they have submitted an additional Terbinafine supplier to the company’s registration dossier a...

Redeye • 08 apr 2024 09:10

Moberg Pharma Q4’2023: Lots of progress in a short time - Redeye

Redeye sees the end-of-year report as results as uneventful.

Redeye • 14 feb 2024 07:26

Moberg Pharma Q4’23: Results in line – focus on Swedish launch - Redeye

Redeye saw a report that came in as expected regarding the results.

Redeye • 13 feb 2024 09:25

Moberg Pharma: Official launch in Sweden of Terclara - Redeye

Redeye comments on the official launch of MOB-015 under the name Terclara in Sweden.

Redeye • 07 feb 2024 09:32

Moberg Pharma: Progressing as planned with approvals and enrollment - Redeye

Redeye views the Q3 report from Moberg Pharma as very much in line with what was expected.

Redeye • 07 nov 2023 14:37

Moberg Pharma Q3’23: National approvals as expected - Redeye

Redeye saw a report that came in more or less as expected.

Redeye • 07 nov 2023 09:54

Moberg Pharma Q3’23: National approvals as expected - Redeye

Redeye saw a report that came in more or less as expected.

Redeye • 07 nov 2023 09:37

Moberg Pharma: Completed enrollment for the Phase 3 study in the US - Redeye

Redeye is encouraged to learn that Moberg Pharma has completed the enrollment to the Phase 3 study for MOB-015 in North America.

Redeye • 06 okt 2023 09:06

Moberg Pharma: Outcome of Rights issue – oversubscribed - Redeye

Redeye briefly comments on the news about the outcome of the rights issue.

Redeye • 01 sep 2023 12:58

Moberg Pharma: Sweden also approved - Redeye

Redeye sees the approval in the Swedish market as the most important in the short perspective as the Swedish market is the first launch mark...

Redeye • 04 aug 2023 08:34

Moberg Pharma Q2: In line with expectations – awaiting issue terms - Redeye

Redeye saw a report that was roughly in line with our expectations.

Redeye • 03 aug 2023 08:56

Moberg Pharma: First market approval - Redeye

Redeye is encouraged by the news that Ireland is the first market to receive national approval for MOB-015 after the decentralized procedure...

Redeye • 31 jul 2023 11:37

Moberg Pharma: EU approval but pressure from delay and share issue - Redeye

Redeye was glad to see that Moberg Pharma received the EU approval within the indicated time frame.

Redeye • 30 jun 2023 08:55

Moberg Pharma: Positive EU approval – launch delay push sales - Redeye

Redeye comments on the EU approval of MOB-015 and the new two-step approach to the EU launch.

Redeye • 28 jun 2023 13:16

Moberg Pharma Q1’23: EU Approval on the horizon - Redeye

Redeye sees a relatively uneventful report with some positive highlights with continued progress in the EU regulatory process and the Phase ...

Redeye • 10 maj 2023 09:18

Moberg Pharma Q1’23: No surprises and on track - Redeye

Redeye’s initial comment on the Q1 report was published earlier this morning.

Redeye • 09 maj 2023 08:50

Moberg Pharma: Termination of license agreement - Redeye

Redeye sees no big drama in the termination of the license agreement with Taisho Pharmaceutical in Japan.

Redeye • 09 mar 2023 09:57

Moberg Pharma: Exciting year ahead - Redeye

Redeye sees a Q4 report that was uneventful as expected.

Redeye • 08 feb 2023 07:46

Moberg Pharma Q4’22: Progress continues as expected - Redeye

Redeye’s initial comment on the Q4 report was published earlier this morning.

Redeye • 07 feb 2023 08:46

Moberg Pharma Q3’22: Steadily moving towards commercialization - Redeye

Redeye’s comments on the Q3 report that was published earlier this morning.

Redeye • 08 nov 2022 10:56

Moberg Pharma Q2’22: On track to Launch - Redeye

Redeye’s comments on the Q2 report that was published earlier this morning.

Redeye • 09 aug 2022 10:11

Moberg Pharma: Lining up strong Partners - Redeye

Redeye is positive about the work done by Moberg Pharma to further strengthen their partner network for MOB-015 and how it points to the str...

Redeye • 05 aug 2022 08:30

Moberg Pharma Q1’22: Real progress in the Quarter - Redeye

Redeye’s comments on the Q1 report that was published earlier this morning.

Redeye • 10 maj 2022 09:32

Moberg Pharma: Adding growth Capital - Redeye

Redeye comments on this morning’s fully guaranteed rights issue.

Redeye • 08 apr 2022 09:48

Moberg Pharma: European application submitted as planned - Redeye

Redeye views the submittal of the full application of the marketing authorization for MOB-015 as positive, although expected.

Redeye • 28 mar 2022 09:00

Moberg Pharma: On path to become the Global Leader - Redeye

Redeye regards this morning’s news about the regulatory submission of the North American phase 3 study as very positive.

Redeye • 18 mar 2022 15:10

Moberg Pharma: On Track to Realize the Potential - Redeye

Redeye makes slight adjustments to the near-term estimates.

Redeye • 16 aug 2021 10:28

Moberg Pharma Q2’21: Progress According to Plan - Redeye

Redeye's initial comment on the Q2 report this morning.

Redeye • 10 aug 2021 14:17